China NT Pharma Group Company Limited (Stock Code: 1011) revealed that on 9 February 2026, it entered into subscription agreements to issue convertible bonds totaling HK$65 million in principal amount. Net proceeds of approximately HK$64 million are intended for general working capital needs and loan repayment.

The bonds carry a 5% annual interest rate over a two-year term, with a conversion price of HK$0.64 per share. Upon full conversion, 101,562,500 new shares would be issued, representing around 15.06% of current issued share capital and approximately 13.09% of the enlarged total.

Conversion shares are to be allotted under the company’s existing General Mandate, which authorizes up to 134,849,203 new shares. No separate shareholders’ approval is required, and no application will be made to list the bonds on any exchange. However, an application will be submitted for the listing of the resultant conversion shares.

Part of the subscription amount will be settled via set-off against existing loans owed by the company. This structure aims to reduce the group’s outstanding liabilities and enhance its balance sheet position. The closing of the convertible bonds issuance remains subject to conditions set out in the subscription agreements. Shareholders and investors are advised to exercise caution when dealing in the company’s securities.